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1. INTRODUCTION 
Patients in critical care can exhibit varying degrees of 
metabolic distress. As a result, treatment is tailored to 
individuals and requires high clinical effort. These variable 
requirements are evident in patients requiring accurate 
glycemic control (AGC). AGC involves targeting of blood 
glucose (BG) to a desired range to mitigate the effects of 
hyperglycemia, while controlling risk of hypoglycemia. 
The implication of AGC is that patients have unfulfilled 
insulin requirements caused by low sensitivity or 
compromised endogenous production. Of interest to this 
paper is the use of the long-acting insulin analogue Glargine 
as exogenous basal insulin. 
Glargine is an insulin analogue with an extremely long action 
period (22-26 hours), characterised by a unique flat peak 
(Campbell et al., 2001). Due to these unique characteristics, 
medical care providers may use the drug to supplement basal 
insulin requirements for patients with persistent 
hyperglycemia. This approach is may typically be used taken 
when a patient is transferred to a less acute ward, where 
constraints on nursing resources may make intensive 
glycemic control impractical. The kinetics and action of 
glargine in these patients has not be fully defined. In 
particular action profiles may show significant variations 
between patients, and the long-acting nature of glargine can 
create additional isuues in typical clinical practice. 
Additionally, glargine may have higher efficacy than other 
forms of insulin [REF]. This paper presents several case 
studies which illustrate a number of areas for concern w with 
glargine use. These examples were collected from 
observations during the pilot study of STAR in Christchurch 
Hospital medical ICU. 
2. METHODS 
2.1 Clinical Data 
Glycemic control data was obtained from 4 patients who took 
part in the STAR Accurate Glycemic Control pilot trial in 
Christchurch hospital. Threeof these patients were 
administered one or more doses of glargine. The patients 
presented here typically transferred on and off STAR as 
dictated by changes in clinical condition and insulin 
requirements. Additional data was extracted from patient 
records to enable idenfitication of insulin sensitivity during 
these periods off intensive glycemic control.  
2.2 ICING and Glargine Models 
Insulin sensitivity was fitted using the clinically validated 
ICING model (Lin et al., 2011) and the Glargine 
Compartment Model. Table I lists the population constants of 
the ICING model defined in Equations 1-6. 
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where G(t) [mmol/L] is the total plasma glucose, I(t) [mU/L] 
is the plasma insulin and interstitial insulin is represented by 
Q(t) [mU/L]. Exogenous insulin input is represented by uex(t) 
[mU/min] and endogenous insulin production is estimated 
with uen [mU/min], modeled as a function of plasma glucose 
concentration determined from critical care patients with a 
minimum pancreatic output of 1U/hr. P1 [mmol] represents 
the glucose in the stomach and P2 [mmol] represents glucose 
in the gut. Enteral glucose input is denoted P(t) [mmol/min]. 
Sensitivity to insulin is observed in the SI parameter. This 
lumped parameter formulation means that SI tracks 
physiological changes in sensitivity to insulin and accounts 
for mis-modelled dynamics. In particular supra-physiologic 
patterns in SI during glargine usage could indicate areas 
where the dynamics of this therapy are not fully captured. 
The Glargine Compartment model captures the kinetics of 
Glargine from injection to appearance in plasma. Glargine 
has four states: precipitate, hexameric, monomeric / dimeric, 
and local interstitium (Wong et al., 2008b, Wong et al., 
2008a). The resulting compartment model is defined in 
Equations 7-12. 
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where pgla(t) [mU] is the total Glargine in precipitate form, 
xh,gla(t) [mU] is the total Glargine in hexameric form, xdm(t) 
[mU] is the total Glargine in monomeric / dimeric form and 
xi(t) [mU] is the total Glargine in the (local) interstitium. The 
exogenous Glargine is represented by up,gla(t) [mU] in the 
precipitate form, um,gla(t) in the monomeric / dimeric form 
and uh,gla(t) in the hexameric form. All other terms and values 
are defined in Table 2, based on an extensive validation study 
(Wong et al., 2008b, Wong et al., 2008a). 
Glargine release from precipitate to hexameric form is a 
saturable process. The maximum dissolution rate, rdis,max 
[mU/min], gives Glargine its unique kinetic profile and is 
defined: 
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where 𝐵𝑟𝑑𝑖𝑠,𝑚𝑎𝑥 [mU/min] is the baseline precipitate 
dissolution rate and 𝑈𝑡𝑟𝑒𝑠  [mU] is the dosage threshold. The 
volume of the Glargine injected also has an effect on the 
kinetics in the form of a diffusive loss from the hexameric 
and monomeric /dimeric states. The rate of this diffusive loss 
kd [min-1] is defined: 
TABLE I 
CONSTANTS USED IN SYSTEM MODEL OF EQUATIONS (1)-(6) 
Model 
var. Description 
Numerical value 
[typical range] 
pG Endogenous glucose clearance 0.006 min-1 
SI Insulin sensitivity 
[1x10-7-1x10-2] 
L/(mU.min)a 
αG 
Saturation of insulin-dependent glucose 
clearance and receptor-bound insulin 
clearance from interstitium 
1/65 L/mU 
d1 
Rate of glucose transfer between the 
stomach and gut -ln(0.5)/20 
d2 
Rate of glucose transfer from the gut to 
the bloodstream -ln(0.5)/100 
Pmax Maximum disposal rate from the gut 6.11 mmol/min 
EGPb 
Basal endogenous glucose production 
(unsuppressed by glucose and insulin 
concentration) 
1.16 mmol/min 
typically 
CNS Non-insulin mediated glucose uptake by the central nervous system 0.3 mmol/min 
VG Glucose distribution volume 13.3 L 
nI, nC 
Rate of transport between plasma and 
interstitial insulin compartments 0.0075 min
-1 
αI 
Saturation of plasma insulin clearance by 
the liver 1.7x10
-3 L/mU 
VI Insulin distribution volume 4.0 L 
xL First-pass hepatic insulin clearance 0.67 
nK 
Clearance of insulin from plasma via the 
renal route 0.0542 min
-1 
nL 
Clearance of insulin from plasma via the 
hepatic route 0.1578 min
-1 
aInsulin sensitivity (SI) is identified from clinical data in the range shown. 
 
TABLE II 
CONSTANTS USED IN SYSTEM MODEL OF EQUATIONS (7)-(12) 
Model 
var. Description Numerical value 
kprep,gla Glargine precipitate dissolution rate 0.0216 min-1 
alphagla Fraction of glargine as precipitate 0.9462 
k1,gla Hexamer dissociation rate 0.0062 min-1 
D 
Diffusion constant for hexameric and 
dimeric/monomeric states 9.00x10-5 cm2/min  
k2 
Dimeric/monomeric insulin transport 
rate into interstitium 0.0106 min-1 
k3 Interstitium transport rate into plasma 0.0618 min-1 
kdi Rate of loss from interstitium 0.029 min-1 
Vx 
Subcutaneous insulin distribution 
volume 11.38 L 
Br_dismax 
Baseline glargine precipitate 
dissolution rate 2.3134 mU/min 
QD 
Hexameric–dimeric equilibrium 
constant 1.50x10-2 ml2/mU2 
Utres Dosage threshold 2.01x103 mU 
   
 
 
 
 
𝒌𝒅 = 𝟑𝑫𝒓                                                                           (14) 
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where r [cm] is the radius of the depot formed by the 
subcutaneous injection and D [cm2/min] is the diffusion 
constant for the hexameric and monomeric /dimeric states.  
Finally the initial quantity of the Dimeric/Monomeric state in 
solution is found by solving the following derived from 
(Wong et al., 2008a): 
𝑸𝑫𝑽𝒊𝒏𝒋 �
𝑼𝒎
𝑽𝒊𝒏𝒋
�
𝟑 + 𝒖𝒎 − 𝒖𝒕𝒐𝒕𝒂𝒍�𝟏 − 𝜶𝒈𝒍𝒂� = 𝟎              (𝟏𝟔)                              
2.3 Glargine Interventions 
Glargine was prescribed as determined by the physician in 
charge, with doses conservatively chosen as half the previous 
daily IV insulin usage. Glargine was given in addition to IV 
Actrapid insulin for highly resistant patients, or as the sole 
exogenous insulin for stable but mildly resistant patients.  
3. RESULTS 
Clinica case A: Clinical nutrition requirements 
Figure 1 presents the clinical course of glargine usage for 
Patient A, and highlights several areas where glargine 
negatively influenced glycemic control.A 30U dose of 
glargine was given at XXX hours. Enteral nutrition was 
halted soon after. The long-acting nature of glargine meant 
the action of insulin persisted for many hours, and in the 
presence of the nutrition stoppage led to a hypoglycemic 
incident, with BG dropping to 2.6mmol/L during the peak of 
the glargine action period and remaining low for the duration 
of the dose. Similar periods of lower BG happened three 
times for this patient around hours XX, XX and XX, with the 
low BG severity limited A) by the presence of parenteral 
nutrition, and B) by the duration of the nutrition stoppage. It 
is also interesting to note the transition on/off AGC. 
Additionally, differences in glycemia are observed between 
AGC (0-160 hrs, 427-463 hrs) and glargine-only periods. The 
patient was initially controlled under STAR and met the 
stopping criteria. Due to apparent stability, glargine was then 
used to meet the patient’s basal insulin requirement, leading 
to BG fluctuating over a wider range. After a hypoglycemic 
event was followed by sustained hyperglycemia STAR was 
restarted, and BG was rapidly brought down to normal 
glycemic levels. 
Clinical cases B & C: Glargine kinetics and efficacy 
Patients B amd C (Figures 2 and 3) illustrate the uncertainty 
surronding the appearance and efficacy of glargine in 
interstitium. Patient B was dosed with 50U of glargine due to 
a high insulin requirement. This relatively conservative 
glargine dose resulted in moderate hypoglycemia, requiring 
intervention with IV dextrose to correct.  
Patient C was initially dosed with 60U of glargine to assist 
with an extended period of mild hyperglycemia whilst 
receiving maximum permitted IV insulin under the STAR 
protocol. This first dose was followed by two 100U doses, 
where the last of these doses preceeded a moderate 
hypoglycemic event. The effect of the glagine dose differed 
 
Figure 1. Patient with regular 30U glargine doses who experienced periods without nutrition, the 
longest of which led to severe hypoglycaemia. 
0 50 100 150 200 250 300 350 400
0
2
4
6
8
10
12
14
B
G
 [m
m
ol
/L
]
0
0.003
0.006
S
I [
L/
(m
U
.m
in
)]
0 50 100 150 200 250 300 350 400
0
100
200
C
on
c.
 [m
m
ol
/L
]
D
os
e 
[U
]
 
 Q Compartment
Glargine dose
0 50 100 150 200 250 300 350 400
0
2
4
6
In
su
lin
 [U
]
N
ut
rit
io
n 
[m
m
ol
/m
in
]
 
 Insulin
Nutrition
Period of AGC Areas of glargine and nutrition reductions 
 
 
 
appeared to differ  between each individual dose in this case. 
Mis-modelling of the glargine dose would appear as changes 
in fitted insulin sensitivity, Although the insulin sensitivity 
peak is confounded by potential changes in patient condition, 
the 50U dose given to Patient B appeared much more 
strongly than expected by the models in literature, where the 
relatively sharp peak conflicts with the expected flat action 
profile. In contrast, the first glargine dose given to Patient C 
approximates the expected appearance profile, whilst the two 
 
Figure 2. Patient with a single dose of glargine, with mismodelling of the dynamics is exhibited as a 
peak of insulin sensitivity. 
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Figure 3. Patient with three doses of glargine, with differing levels of appearance between doses. 
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100U doses were correlated with a rise in fitted insulin 
sensitivity. This rise in insulin sensitivity may be due to 
change in patient condition or the action profile of glargine, 
and cannot be further resolved in this case.. 
Clinical case D: Patient insulin sensitivity variation 
Patient D (Figure 4) illustrates the dynamic changes in 
insulin requirement. This patient was well controlled under 
the STAR protocol, with BG measures within the 4.4-
8.0mmol/L target over the entire period, and would have been 
a likely candidate for glargine usage, particularly over the last 
few days of ICU stay. For the first 4 days patient condition is 
stable, with moderate to high insulin requirement. At the end 
of the 5th day, insulin requirement is dramatically reduced, 
and is removed altogether on the 6th. Glargine doses given on 
the 4th-6th day would have likely resulted in greater risk of 
hypoglycemia, given the very rapid rise in sensitivity to 
insulin, coupled with the long-last, non-reversible effect of 
glargine. 
4. DISCUSSION 
The clinical case studies presented here indicate that 
adequately considering nutritional requirements is of critical 
importance for safe usage of glargine in critical care. Patient 
A (Figure 1) was regularly dosed with glargine, but nutrition 
was inconsistent, leading to a major hypoglycemic incident. 
Enteral nutrition was stopped three times during the glargine-
only period, with the severity of the outcome determined by 
the length of the stoppage and the presence of parenteral 
nutrition. As it was not an isolated event, this case study 
indicates that nutrition intake must be carefully monitored to 
ensure adequate safety, and that adequate nutrition is supplied 
throughout the entire ~24-hour action period of glargine. 
The contrast between controlled and uncontrolled glycemia 
for Patient A displayed the propensity for uncontrolled BG to 
be persistently hyperglycemic when a patient has an 
unfulfilled exogenous insulin requirement. Sensitivity to 
changes in nutrition was displayed after the major 
hypoglycemic incident, as the restart rate was approximately 
20% higher than the rate prior to stoppage, and led to 
exacerbated hyperglycemia. AGC was required to bring BG 
back under control, and was able to do so rapidly. However, 
after STAR was stopped for the second time, BG rose again 
and persisted in the mild hyperglycemic range. This 
sensitivity to nutrition suggests that AGC protocols should be 
designed to take nutrition into account, either through direct 
control (such as STAR) or by design for use with specific 
rates. The BG profile suggests insulin requirement might be 
preferred over BG stability as a stopping criteria for AGC, 
requiring metabolic self-sufficiency before control is 
completely stopped. This case also highlights the integrated 
nature of the insulin-glucose-nutrition system can result in 
complex clinical interactions. 
Uncertainty in both the pharmacokinetics and 
pharmacodynamics will make prospective dosing of glargine 
difficult. Peaks in the observed insulin sensitivity profile 
indicate the model is not completely capturing either the 
kinetics or the dynamics in Figure 2, contrasting with the 
profile of Figure 3. Figure 3 also suggests the profile can vary 
between dose, not just between patient, so prior behavior is 
potentially not indicative of future response. 
A final cautionary note warns that patient condition can 
change dramatically over a few hours, having a large effect 
 
Figure 4. Patient displaying the significant changes in insulin requirement, shown by a steady rise in 
insulin sensitivity. 
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on a patient’s apparent insulin requirement. The long action 
period and non-reversible nature of glargine presents a 
potential problem with patients similar to Figure 4, where a 
sudden rise in insulin sensitivity removed all requirement for 
exogenous insulin to maintain normoglycemia over the 
course of several hours. Such a patient would be at risk of 
severe hypoglycemia if previously dosed with glargine during 
the stable period of high insulin requirement. Glargine is 
typically used when a patient requires additional insulin 
under AGC, or is deemed stable and thus no longer requires 
such intense observation. Thus, this case study displays the 
potential for longer acting insulin analogues to put patient 
safety at risk when metabolic conditions quickly change. 
With these clinical results showing hypoglycemia in each of 
the patients dosed with glargine during the STAR trial, safety 
is clearly an issue. Despite conservative dosing (half of the 
prior daily insulin requirement) two cases resulted in severe 
hypoglycemia (< 2.2 mmol/L). It is also important to note 
that none of the severe hypoglycemic events can be attributed 
to failing of AGC, as in each case either exogenous insulin 
was previously stopped by the protocol or AGC had been 
discontinued. These episodes suggest more research is 
required to investigate the effects of glargine in an intensive 
care population. 
A potential solution to utilize glargine safely in intensive care 
may be to use glargine in conjuction with a specifically 
designed low-effort AGC protocol that may employ faster-
acting insulins. With more information on glargine in 
intensive care populations, a conservative low-dose glargine 
regimen could be used to replace a patient’s basal insulin 
requirement while the AGC protocol responds to intra-day 
variability. Taking advantage of the extended timescale of 
glargine has the potential to reduce effort, with risk addressed 
by an effective AGC protocol. 
5.  CONCLUSIONS 
Clinical results from glargine usage during the STAR pilot 
trial suggest that use of glargine in the ICU can present 
unaddressed risks, compounded by uncertainty on the 
behavior of glargine in this population. Extended timescales 
increase the potential for changes in patient condition to 
negatively affect safety, while reducing the tolerance for 
clinical events such as nutrition stoppages. Further research 
appears necessary to set the stage for prospective dosing to 
reduce the risks associated with the long action insulin 
analogue. 
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